U.S. companies may see opportunities to increase collaborations amongst one another during the current pandemic, but should be aware that they are still subject to the antitrust laws.
The post Competitor Collaborations in the U.S. During COVID-19 appeared first on Life Sciences Perspectives.
Related Content
- Big Molecule WatchJuly 25, 2024
FDA Issues Draft Guidance on Demonstrating Biosimilar Interchangeability
- Big Molecule WatchJuly 25, 2024
FDA Approves Samsung’s Eculizumab Biosimilar
- Life Sciences PerspectivesJuly 24, 2024
Common FDA Bioresearch Monitoring (BIMO) Violations: Updates from FY 2023 to Now
- AlertJuly 24, 2024
Common FDA Bioresearch Monitoring (BIMO) Violations: Updates from FY 2023 to Now
- Big Molecule WatchJuly 23, 2024
FTC Issues Interim Report on Ongoing Study of Pharmacy Benefit Managers
- Alert19 July 2024
Historic New Listing Rules Adopted for the UK
- AlertJuly 17, 2024
CTA Update: FinCEN Clarifies BOI Reporting Requirements for Dissolved Reporting Companies
- Big Molecule WatchJuly 12, 2024
Outlook Therapeutics Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma)
- Speaking EngagementsJuly 31, 2024 | 2:00 PM - 3:15 PM ET
ACS Webinar - Avoiding IP Own Goals in Drug Discovery: Best Practices for Obtaining (and Keeping) Your IP
- Press ReleaseJuly 24, 2024
Goodwin Advises Third Arc Bio on Oversubscribed $165 Million Series A Launch
- Press ReleaseJuly 18, 2024
Lantheus Acquires Global Rights to Life Molecular Imaging’s (“Life Molecular”) Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
- Awards and RankingsJuly 18, 2024
Goodwin Leads the H1 2024 League Table Rankings
- Awards and RankingsJuly 16, 2024
James Ding, Lynette Elam, and Peter Hanoian Named Law360 Rising Stars
- Press ReleaseJuly 11, 2024
Ascidian Therapeutics and Roche Collaborate on RNA Exon Editing for Neurological Diseases; Ascidian to Receive $42 Million Initial Payment, and Up to $1.8 Billion in Research, Clinical and Commercial Milestone Payments
- Press ReleaseJuly 9, 2024
Vigil Neuroscience Receives $40 Million Strategic Investment From Sanofi
- Press ReleaseJuly 8, 2024
Morphic Holding, Inc. to be Acquired by Eli Lilly and Company For $3.2 Billion